NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe
Key Highlights
- ➤EPO grants NUC-7738 composition-of-matter patent EP 3683225 in Europe
- ➤NUC-7738 patent protection now exceeds 85 issued patents worldwide
- ➤NUC-7738 is in Phase 2 of NuTide:701 with Keytruda in resistant metastatic melanoma
- ➤Cash resources expected to fund planned operations into 2029
Expert Statements
Hugh S. Griffith, Founder and Chief Executive Officer of NuCana
“We are delighted that the EPO has granted this important new patent, which further strengthens the intellectual property protection of NUC-7738 and reflects the strength and novelty of our science.”
Hugh S. Griffith, Founder and Chief Executive Officer of NuCana
“This composition-of-matter patent is a critical addition to our global patent estate for NUC-7738, which now spans over 85 issued patents worldwide, and builds upon similar composition-of-matter patents previously granted in both the United States and China.”
Hugh S. Griffith, Founder and Chief Executive Officer of NuCana
“This underscores our commitment to protecting NUC-7738's long-term commercial potential across all major markets.”
Hugh S. Griffith, Founder and Chief Executive Officer of NuCana
“With cash resources expected to fund our planned operations into 2029, we believe we are well positioned to advance the clinical development of NUC-7738 and to deliver on a number of important milestones over the remainder of 2026 as we work to bring meaningful new treatment options to patients with cancer.”
EDINBURGH, United Kingdom, Sept. 30, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced that the European Patent Office (“EPO”) has granted an important patent covering the composition of matter for NUC-7738.
This patent (EP 3683225) is a key component of the patent protection for NUC-7738, which currently consists of over 85 issued patents worldwide. The composition-of-matter patent covers the chemical structure of NUC-7738, NuCana’s novel anti-cancer agent currently being evaluated in the Phase 2 part of a Phase 1/2 clinical study (NuTide:701) in combination with Keytruda(®) (pembrolizumab) in patients with PD-1 inhibitor-resistant metastatic melanoma.
Get started
Create a free account to read the full story.